Abvc biopharma executes a global licensing term sheet for oncology/hematology products, expecting licensing income of $55m and royalties of up to $50m

Fremont, ca, april 10, 2024 (globe newswire) -- via newmediawire --  abvc biopharma, inc.  (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that the company together with its affiliates biolite, inc., and rgene corporation entered into a term sheet with oncox biopharma, inc. (oncox) for the company's oncology/hematology pipeline(the "licensed products"). subject to negotiation and execution of the definitive agreement, this license would cover the licensed products' clinical trial, registration, manufacturing, supply, and distribution rights. abvc is set to receive $50,000,000 as licensing fees in the form of cash/shares within 30 days of execution of the definitive agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and royalties of 5% of net sales, up to $50,000,000, after the launch of the licensed products.
ABVC Ratings Summary
ABVC Quant Ranking